NCT00704847

Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)

A Randomized, Double-Blind, Multi-Center, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Subjects With Knee Osteoarthritis

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,030 (actual)
• Sponsor: Nordic Bioscience A/S · Industry
• Sex: All
• Age: 51 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this phase III study is to Evaluate the Efficacy and Safety of Oral Salmon Calcitonin in the Treatment of Patients with Osteoarthritis of the Knee

Conditions

• Osteoarthritis

Interventions

Type	Name	Description
DRUG	Oral Salmon Calcitonin	0.8mg SMC021, twice daily
DRUG	Oral Salmon Calcitonin (Placebo)	0.8mg Placebo, twice daily

Timeline

• Start date: 2008-06-01
• Primary completion: 2011-05-01
• Completion: 2011-06-01
• First posted: 2008-06-25
• Last updated: 2019-04-24
• Results posted: 2012-09-12

Locations

18 sites across 10 countries: United States, Belgium, Canada, Czechia, Denmark, Hong Kong, Poland, Romania, Spain, United Kingdom